Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654265 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL4634087 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL6624016 | 0.95 | ALDH1A1 (0.49) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL6625376 | 0.95 | ALDH1A1 (0.49) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL8187290 | 0.94 | CTSK (0.48) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL8385337 | 0.89 | ALDH1A1 (0.49) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL9807069 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL9807067 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL9327734 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CTSKCTSBCTSSCTSL | |
| SCHEMBL7554462 | 0.85 | ALDH1A1 (0.47) | ALDH1A1CTSKCTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | ALDH1A1 3874/4885CTSK 112/4885CTSB 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.